|1.||Obniska, Jolanta: 5 articles (11/2009 - 11/2004)|
|2.||Aoki, Takumi: 2 articles (01/2014 - 11/2013)|
|3.||Nakadera, Yasuhito: 2 articles (01/2014 - 11/2013)|
|4.||Yamada, Masateru: 2 articles (01/2014 - 11/2013)|
|5.||Yagi, Mai: 2 articles (01/2014 - 11/2013)|
|6.||Higashi, Eriko: 2 articles (01/2014 - 11/2013)|
|7.||Nishimura, Yutaka: 2 articles (01/2014 - 11/2013)|
|8.||Watanabe, Ayano: 2 articles (01/2014 - 11/2013)|
|9.||Fuchi, Nobuhiro: 2 articles (01/2014 - 11/2013)|
|10.||Kato, Yuko: 2 articles (01/2014 - 11/2013)|
11/01/2009 - "The most active were N-(2-methoxyphenyl)- [V] and N-(4-chlorophenyl-amino)-2-azaspiro[4.5]decane-1,3-dione [XI] that inhibited seizures at a dose of 100 mg/kg in the scPTZ and MES tests, respectively. "
11/01/2004 - "The most potent of the series were N-(2-methylphenyl)-2-aza-spiro[4.5]decane-1,3-dione [III] and N-(3-methylphenyl)-2-aza-spiro [4.5]decane-1,3-dione [IV], which inhibited seizures in the MES and sc.MET tests. "
11/24/1949 - "The effects of bis-trimethylammonium decane diiodide and dibromide on neuromuscular function and on induced convulsions in man."
03/01/2006 - "Among those molecules the most potent were N-(4-methylphenyl)-amino-2-azaspiro[4.4]nonane-1,3-dione [V], N-(2-trifluoromethylphenyl)-amino-2-azaspiro[4.4]nonane-1,3-dione [VI], N-(3-methylphenyl)-amino-2-azaspiro[4.5]decane-1,3-dione [VIII] and N-(4-methylphenyl)-amino-6-methyl-2-azaspiro[4.5]decane-1,3-dione [XIV], which inhibited the seizures mainly in the sc. "
11/01/2004 - "A series of N-phenyl-2-aza-spiro[4.5]decane-1,3-diones [III-VIIII] structurally related to the previously described N-phenyl-3-arylpyrrolidine-2,5-dione (11) was synthesized and tested for their anticonvulsant activity in the maximum electroshock seizure (MES) and metrazole seizure threshold (sc. "
08/01/1997 - "One of these compounds, SK&F 106615 (N,N-diethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-propanamine++ + dihydrochloride), is now in phase II clinical trials for rheumatoid arthritis. "
07/11/2005 - "Atiprimod (2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5] decane dimaleate) has exerted anti-inflammatory activities and inhibited oeteoclast-induced bone resorption in animal models and been well tolerated in patients with rheumatoid arthritis in phase I clinical trials. "
07/23/2015 - "(18)F-Labeled 1,4-Dioxa-8-azaspiro[4.5]decane Derivative: Synthesis and Biological Evaluation of a σ1 Receptor Radioligand with Low Lipophilicity as Potent Tumor Imaging Agent."
03/01/2015 - "Simulating the relatively fatty consistency of cancer tissue by diluting the samples in n-decane, surprisingly reduces their tendency to decompose to lifetimes of weeks even at room temperature. "
01/01/2014 - "Recently, we have shown that Roslin 2 or R2 (1-benzyl-15,3,5,7-tetraazatricyclo[220.127.116.11~3,7~]decane) compound disrupts FAK and p53 proteins, activates p53 transcriptional activity, and blocks tumor growth. "
11/15/2012 - "Tail-tail dimer 9a was shown to be active in a breast and in an ovary tumor model, highlighting the potential of dimeric Smac mimetics/IAP inhibitors based on the N-AVPI-like 4-substituted 1-aza-2-oxobicyclo[5.3.0]decane scaffold as potential antineoplastic agents."
05/01/2012 - "A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [18.104.22.168(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo."
05/01/2012 - "Using an intensified spectroscopic detector CCD and a heated shock tube, transient emission spectra of n-decane in the combustion reaction were measured in a spectral range of 200-850 nm. Experiments were conducted at temperatures of 1100-1600 K, a pressure of 2.0 atm, an initial fuel mole fraction of 1.0% and an equivalence ratio of 1.0. "
05/01/2014 - "In this work, a new reduced chemical kinetic mechanism for fuel n-decane, which selected as a surrogate fuel for kerosene, containing 210 elemental reactions (including 92 reversible reactions and 26 irreversible reactions) and 50 species was developed, and the ignition and combustion characteristics of this fuel in both shock tube and flat-flame burner were kinetic simulated using this reduced reaction mechanism. "
08/21/2007 - "Experimentally derived and numerically predicted ignition delays of n-heptane-air and n-decane-air mixtures in high-pressure shock tubes in a wide range of temperatures, pressures and equivalence ratios agree very well. "
03/01/1992 - "SK&F 105.685 (N,N-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-propanamine+ ++ dihydrochloride) is a novel azaspirane with beneficial activity in rat models of adjuvant-induced arthritis and experimental autoimmune encephalomyelitis as well as in the murine lupus model. "
06/01/2005 - "Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine; trade name, Atiprimod) is an orally bioavailable cationic amphiphilic compound that significantly inhibits production of interleukin 6 (IL-6) and inflammation in rat arthritis and autoimmune animal models. "
02/01/1993 - "SK&F 105685 (N,N-dimethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine+ ++ dihydrochloride) is a novel azaspirane with beneficial activity in animal models of autoimmune disease such as adjuvant-induced arthritis and experimental encephalomyelitis in the Lewis rat and lupus-like disease in the MRL mouse. "
|10.||Asp(5)- oxytocin (OXA)
|2.||Drug Therapy (Chemotherapy)